Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

335 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Factors influencing lopinavir and atazanavir plasma concentration.
Stöhr W, Back D, Dunn D, Sabin C, Winston A, Gilson R, Pillay D, Hill T, Ainsworth J, Gazzard B, Leen C, Bansi L, Fisher M, Orkin C, Anderson J, Johnson M, Easterbrook P, Gibbons S, Khoo S; UK CHIC Steering Committee. Stöhr W, et al. Among authors: easterbrook p. J Antimicrob Chemother. 2010 Jan;65(1):129-37. doi: 10.1093/jac/dkp408. J Antimicrob Chemother. 2010. PMID: 19897506 Free PMC article.
Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count.
Phillips AN, Gazzard B, Gilson R, Easterbrook P, Johnson M, Walsh J, Leen C, Fisher M, Orkin C, Anderson J, Pillay D, Delpech V, Sabin C, Schwenk A, Dunn D, Gompels M, Hill T, Porter K, Babiker A; UK Collaborative HIV Cohort Study. Phillips AN, et al. Among authors: easterbrook p. AIDS. 2007 Aug 20;21(13):1717-21. doi: 10.1097/QAD.0b013e32827038bf. AIDS. 2007. PMID: 17690569
Changes in outcome of persons initiating highly active antiretroviral therapy at a CD4 count less than 50 Cells/mm3.
Porter K, Walker S, Hill T, Anderson J, Leen C, Johnson M, Gazzard B, Walsh J, Fisher M, Orkin C, Schwenk A, Gilson R, Easterbrook P, Delpech V, Sabin CA; UK CHIC Study Group. Porter K, et al. Among authors: easterbrook p. J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):202-5. doi: 10.1097/QAI.0b013e31815b1291. J Acquir Immune Defic Syndr. 2008. PMID: 17971709
Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study.
Phillips AN, Leen C, Wilson A, Anderson J, Dunn D, Schwenk A, Orkin C, Hill T, Fisher M, Walsh J, Pillay D, Bansi L, Gazzard B, Easterbrook P, Gilson R, Johnson M, Sabin CA; UK Collaborative HIV Cohort (CHIC) Study. Phillips AN, et al. Among authors: easterbrook p. Lancet. 2007 Dec 8;370(9603):1923-8. doi: 10.1016/S0140-6736(07)61815-7. Lancet. 2007. PMID: 18068516
Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression?
Bansi LK, Benzie AA, Phillips AN, Portsmouth S, Hill T, Leen C, Schwenk A, Johnson M, Anderson J, Gilson R, Easterbrook P, Gazzard B, Fisher M, Orkin C, Porter K, Pillay D, Taylor GP, Walsh JC, Sabin CA; UK Collaborative HIV Cohort (UK CHIC) Study. Bansi LK, et al. Among authors: easterbrook p. AIDS. 2008 Jan 30;22(3):349-56. doi: 10.1097/QAD.0b013e3282f4709a. AIDS. 2008. PMID: 18195561
The associations between age and the development of laboratory abnormalities and treatment discontinuation for reasons other than virological failure in the first year of highly active antiretroviral therapy.
Sabin CA, Smith CJ, Delpech V, Anderson J, Bansi L, Gilson R, Schwenk A, Leen C, Gazzard B, Porter K, Mackie N, Fisher M, Orkin C, Johnson M, Easterbrook P, Hill T, Phillips AN; UK Collaborative HIV Cohort (CHIC) Study. Sabin CA, et al. Among authors: easterbrook p. HIV Med. 2009 Jan;10(1):35-43. doi: 10.1111/j.1468-1293.2008.00654.x. Epub 2008 Nov 10. HIV Med. 2009. PMID: 19018876 Free article.
Is 1 alanine transaminase >200 IU enough to define an alanine transaminase flare in HIV-infected populations? A new definition derived from a large cohort study.
Bansi L, Turner J, Gilson R, Post F, Gazzard B, Leen C, Anderson J, Porter K, Hill T, Fisher M, Ainsworth J, Pillay D, Johnson M, Winston A, Orkin C, Easterbrook P, Phillips A, Sabin C; UK Collaborative HIV Cohort Study. Bansi L, et al. Among authors: easterbrook p. J Acquir Immune Defic Syndr. 2009 Nov 1;52(3):391-6. doi: 10.1097/QAI.0b013e3181ab73cc. J Acquir Immune Defic Syndr. 2009. PMID: 19553826
Virological response to initial antiretroviral regimens containing abacavir or tenofovir.
Bansi L, Sabin C, Gilson R, Gazzard B, Leen C, Anderson J, Dunn D, Hill T, Fisher M, Ainsworth J, Pillay D, Johnson M, Walsh J, Orkin C, Easterbrook P, Gompels M, Phillips A; UK Collaborative HIV Cohort Study. Bansi L, et al. Among authors: easterbrook p. J Infect Dis. 2009 Sep 1;200(5):710-4. doi: 10.1086/605024. J Infect Dis. 2009. PMID: 19635022
Discordant responses on starting highly active antiretroviral therapy: suboptimal CD4 increases despite early viral suppression in the UK Collaborative HIV Cohort (UK CHIC) Study.
Gilson RJ, Man SL, Copas A, Rider A, Forsyth S, Hill T, Bansi L, Porter K, Gazzard B, Orkin C, Pillay D, Schwenk A, Johnson M, Easterbook P, Walsh J, Fisher M, Leen C, Anderson J, Sabin CA; UK Collaborative HIV Cohort Study Group. Gilson RJ, et al. HIV Med. 2010 Feb;11(2):152-60. doi: 10.1111/j.1468-1293.2009.00755.x. Epub 2009 Sep 1. HIV Med. 2010. PMID: 19732175 Free article.
Tuberculosis among people with HIV infection in the United Kingdom: opportunities for prevention?
Grant AD, Bansi L, Ainsworth J, Anderson J, Delpech V, Easterbrook P, Fisher M, Gazzard B, Gilson R, Gompels M, Hill T, Johnson M, Leen C, Orkin C, Phillips AN, Porter K, Post F, Walsh J, Sabin CA; United Kingdom Collaborative HIV Cohort Study Group. Grant AD, et al. Among authors: easterbrook p. AIDS. 2009 Nov 27;23(18):2507-15. doi: 10.1097/QAD.0b013e3283320dfd. AIDS. 2009. PMID: 19770622
335 results